Wall Street Zen Upgrades aTyr Pharma Stock to Hold

Analysts cite potential in biotech company's pipeline of rare disease treatments.

Mar. 15, 2026 at 5:11am

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has upgraded its rating on aTyr Pharma (NASDAQ: ATYR) from "sell" to "hold" in a new report. The biotechnology company, headquartered in San Diego, California, is focused on developing novel protein-based therapies for rare and serious diseases.

Why it matters

The upgrade from Wall Street Zen could signal a shift in sentiment around aTyr Pharma, which has struggled with its stock price over the past year. The company's pipeline of potential treatments for conditions like pulmonary sarcoidosis, muscular dystrophy, and solid tumors has generated interest, but concerns about its financial position and clinical progress have weighed on the share price.

The details

In its report, Wall Street Zen cited aTyr Pharma's proprietary Extracellular Modulation platform and the potential of its drug candidates as reasons for the upgraded rating. The firm noted that while challenges remain, the company's focus on rare diseases could provide opportunities for growth and value creation.

  • aTyr Pharma's stock opened at $0.85 on Friday, March 15, 2026.
  • The company's 50-day simple moving average is $0.85, and its 200-day simple moving average is $1.26.
  • aTyr Pharma reported its latest quarterly earnings on Thursday, March 5, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

aTyr Pharma

A clinical-stage biotechnology company focused on developing novel protein-based therapies for rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

Analysts will be closely watching aTyr Pharma's progress in its clinical trials and pipeline development as the company seeks to capitalize on the upgraded rating and potential opportunities in the rare disease treatment market.

The takeaway

The upgrade from Wall Street Zen reflects a cautious optimism around aTyr Pharma's potential, as the company continues to navigate the challenges of developing novel therapies for rare and serious diseases. Investors will be closely monitoring the company's progress in the coming months and years.